Federman & Sherwood Investigates Gerson Lehrman Group for Data Breach
Federman & Sherwood Investigates Gerson Lehrman Group for Data Breach
The law firm of Federman & Sherwood has initiated an investigation into Gerson Lehrman Group with respect to their recent data breach. On March 12, 2024, Gerson Lehrman Group notified individuals that the company experienced a data breach after an unauthorized party accessed sensitive consumer data entrusted to the company. According to Gerson Lehrman Group, they determined that information stored on their servers may have been subject to unauthorized access on November 12, 2023. Gerson Lehrman Group determined that the information exposed in the data breach includes: name and Social Security number.
If you wish to discuss this action, obtain further information, and/or participate in this litigation, please contact Lacrista A. Bagley either by email at lab@federmanlaw.com or visit our firm’s website www.federmanlaw.com.
Lacrista A. Bagley
lab@federmanlaw.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313565338/en/
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track